


## DBCO-(PEG)3-VC-PAB-MMAE

<b>Cat. No.:</b>	HY-111012
<b>CAS No.:</b>	2754384-60-4
<b>Molecular Formula:</b>	C <sub>86</sub> H <sub>124</sub> N <sub>12</sub> O <sub>18</sub>
<b>Molecular Weight:</b>	1613.97
<b>Target:</b>	Drug-Linker Conjugates for ADC
<b>Pathway:</b>	Antibody-drug Conjugate/ADC Related
<b>Storage:</b>	-20°C, stored under nitrogen * The compound is unstable in solutions, freshly prepared is recommended.



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 60 mg/mL (37.18 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	<b>Preparing Stock Solutions</b>	<b>1 mM</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>5 mM</b>	0.6196 mL	3.0980 mL	6.1959 mL
		<b>10 mM</b>	0.1239 mL	0.6196 mL	1.2392 mL
	<b>10 mM</b>	0.0620 mL	0.3098 mL	0.6196 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 1.5 mg/mL (0.93 mM); Suspended solution; Need ultrasonic				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 1.5 mg/mL (0.93 mM); Suspended solution; Need ultrasonic				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1.5 mg/mL (0.93 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	DBCO-(PEG)3-VC-PAB-MMAE is a agent-linker conjugate for ADC. DBCO-(PEG)3-VC-PAB-MMAE is made by <a href="#">Monomethyl auristatin E</a> (HY-15162) conjugates to DBCO-(PEG)3-vc-PAB linker. DBCO-(PEG)3-VC-PAB-MMAE can be used for the research of cancer <sup>[1]</sup> . DBCO-(PEG)3-VC-PAB-MMAE is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
<b>IC<sub>50</sub> &amp; Target</b>	Auristatin

---

## CUSTOMER VALIDATION

- Nat Commun. 2023 Feb 21;14(1):974.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

---

## REFERENCES

[1]. Karsten L, et al. Bivalent EGFR-Targeting DARPIn-MMAE Conjugates. Int J Mol Sci. 2022 Feb 23;23(5):2468.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA